Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xvivo Perfusion AB ( (SE:XVIVO) ) just unveiled an announcement.
XVIVO Perfusion’s nomination committee has corrected its earlier communication ahead of the 27 April 2026 annual general meeting to clarify that board member Göran Dellgren is proposed for re-election. The updated slate now includes the re-election of Gösta Johannesson, Camilla Öberg, Erik Strömqvist, Dellgren and Paul Marcun, while current directors Lars Henriksson and Lena Höglund have declined to stand again.
The committee is also proposing the election of two new board members, industry veterans Emil Billbäck and Anne-Karen Hunt, both deemed independent of the company, management and major shareholders. Their extensive international experience in healthcare and medtech, including senior roles at Bonesupport, GE Healthcare and Demant, is set to strengthen XVIVO’s governance and strategic capabilities as it advances its position in the global organ transplantation market.
The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK198.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company founded in 1998 that focuses exclusively on extending the viable life of major organs for transplantation. Its organ preservation and perfusion solutions are used by transplant teams and researchers globally, and the company is headquartered in Gothenburg with operations on two continents and a listing on Nasdaq Stockholm under the ticker XVIVO.
Average Trading Volume: 182,948
Technical Sentiment Signal: Sell
Current Market Cap: SEK5.69B
See more data about XVIVO stock on TipRanks’ Stock Analysis page.